When the Body Turns on the Pregnancy: Immune Factors in Recurrent Miscarriage

Recurrent pregnancy loss — defined by most medical organizations as two or more clinical pregnancy losses — affects approximately one to two percent of couples attempting to conceive. For those who have experienced it, the grief is compounded by a question that standard testing often fails to answer: why? Chromosomal abnormalities in the embryo account for a large proportion of sporadic miscarriages, but in cases of recurrence, particularly when embryos have been screened and found to be chromosomally normal, the explanation is frequently elusive.

In recent years, reproductive immunology has emerged as a framework for understanding a subset of these losses — one that centers not on the embryo, but on the maternal immune environment in which it must survive.

The Immune Paradox of Pregnancy

A successful pregnancy requires one of biology's most remarkable feats of tolerance. The developing embryo carries genetic material from both parents, meaning it is, from an immunological standpoint, partially foreign to the mother's body. Under ordinary circumstances, the immune system is precisely calibrated to identify and eliminate foreign material. That it does not destroy the embryo — at least in the majority of pregnancies — reflects an elaborate and still incompletely understood process of immune modulation.

At the maternal-fetal interface, a specialized population of immune cells called uterine natural killer (uNK) cells plays a central role. Unlike peripheral natural killer cells, which function primarily as defenders against pathogens and aberrant cells, uNK cells are thought to support early placental development, regulate blood vessel formation in the uterine lining, and participate in the tolerance mechanisms that protect the embryo. Regulatory T cells (Tregs) also contribute to this environment, suppressing excessive immune responses that might otherwise target fetal tissue.

When this immune architecture is disrupted — whether through overactivation, underactivation, or dysregulation — implantation may fail, or an early pregnancy may not be sustained.

Recognized Immunological Causes of Pregnancy Loss

Not all immune-related contributors to miscarriage are speculative. Several have a substantial body of evidence behind them and are considered part of standard clinical evaluation.

Antiphospholipid syndrome (APS) is the most clearly established immunological cause of recurrent pregnancy loss. APS is an autoimmune condition in which the body produces antibodies — most notably anticardiolipin antibodies, anti-beta-2 glycoprotein I antibodies, and lupus anticoagulant — that increase the risk of blood clot formation in placental vessels, compromising fetal blood supply. APS is diagnosable through standardized blood tests and is treated with a combination of low-dose aspirin and low molecular weight heparin, a protocol that has been shown in clinical trials to significantly improve live birth rates in affected individuals.

Testing for antiphospholipid antibodies is recommended by the American Society for Reproductive Medicine (ASRM) as part of the standard workup for recurrent pregnancy loss and should be considered early in the evaluation process.

Thyroid autoimmunity represents another well-studied connection. The presence of thyroid peroxidase (TPO) antibodies — even in individuals with normal thyroid hormone levels — has been associated with elevated miscarriage risk. While the mechanism is not fully understood, some research suggests that levothyroxine supplementation may reduce miscarriage rates in TPO-antibody-positive individuals who are euthyroid, though evidence remains somewhat heterogeneous.

The Less Settled Territory: Emerging and Contested Immune Factors

Beyond APS and thyroid autoimmunity, reproductive immunology enters considerably murkier waters — an area where clinical practice sometimes outpaces the evidence, and where patients must be especially discerning.

Natural killer cell testing and elevated uNK cells. Peripheral blood NK cell assays and uterine NK cell biopsies are offered by some specialized clinics as part of an expanded immune workup. Elevated uNK cell activity has been proposed as a mechanism of implantation failure and early loss. However, the interpretation of these tests is not standardized, reference ranges vary significantly between laboratories, and robust randomized controlled trial data supporting NK-cell-directed treatment — such as intravenous immunoglobulin (IVIG) or intralipid infusions — remain limited. Major reproductive medicine societies, including ASRM, do not currently endorse routine NK cell testing as part of standard care.

HLA compatibility and immune tolerance. Some researchers have explored whether sharing too many human leukocyte antigen (HLA) markers between partners may impair the immune recognition processes that normally support tolerance of the embryo. This hypothesis has generated interest but has not translated into validated clinical interventions.

Chronic endometritis. Distinct from the immune conditions above, chronic endometritis — a low-grade bacterial infection of the uterine lining — deserves particular mention because it sits at the intersection of infectious and immune pathology. Studies have found higher rates of chronic endometritis in women with recurrent implantation failure and recurrent miscarriage, and antibiotic treatment has been associated with improved outcomes in several series. Diagnosis typically requires endometrial biopsy with specialized staining for plasma cells. While not yet universally incorporated into evaluation protocols, awareness of this condition is growing among reproductive specialists.

Separating Evidence from Enthusiasm

Patients who have experienced multiple losses are, understandably, motivated to pursue every available avenue of investigation and treatment. This vulnerability is sometimes exploited by clinics offering extensive immune panels and aggressive interventions — including corticosteroids, IVIG, TNF-alpha inhibitors, and others — outside of research settings and without adequate evidence of benefit.

This is not to suggest that immunological treatment is never appropriate. For individuals with confirmed APS, treatment is well-supported and effective. For those with thyroid autoimmunity, monitoring and potential supplementation are reasonable. For cases of chronic endometritis, targeted antibiotic therapy has a plausible mechanism and supporting data. The difficulty lies in the gray zone: interventions directed at immune abnormalities detected by non-standardized tests, in the absence of a confirmed diagnosis, carry both financial costs and potential medical risks.

Questions worth raising with any provider recommending immune-directed treatment include: What specific diagnosis does this test aim to confirm? What does the peer-reviewed literature say about this intervention? Is this being offered within a clinical trial or as standard of care?

Moving Forward After Loss

For individuals navigating recurrent miscarriage, a thorough evaluation — including chromosomal analysis of both partners, uterine anatomy assessment, antiphospholipid antibody testing, thyroid function and antibody screening, and in some cases endometrial biopsy — provides a reasonable starting framework aligned with current evidence-based guidelines.

Where standard evaluation does not yield answers, consultation with a specialist in reproductive immunology or a reproductive endocrinologist with expertise in recurrent loss may open additional diagnostic avenues. The field is genuinely advancing, and research underway today may reshape clinical practice within the next decade.

What the science makes clear, even now, is that recurrent pregnancy loss is rarely a single-cause phenomenon. The immune system is one piece of a complex biological puzzle — and understanding its role, with appropriate nuance, is a meaningful step toward finding answers.